Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Palo Alto Networks Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Palo Alto Networks Inc trades at $328.49 (market cap $265.62B). The key difference: Palo Alto Networks Inc is far larger — about 6.7× Alnylam Pharmaceuticals, Inc.'s market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | PANW | |
|---|---|---|
Market Cap | $39.89B | $265.62B |
Sector | Health | Technology |
52-Week High | $491.22 | $357.53 |
52-Week Low | $278.09 | $141.67 |
Enterprise Value | $38.15B | $264.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Palo Alto Networks (PANW) trades at $325.91, down 3.67% today, but maintains strong analyst support with 74% buy ratings and a $334.71 consensus target. The stock shows bullish technical signals with support at $321 and resistance at $347. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.85 surpassing the $0.793 estimate. Revenue growth remains robust, climbing from $5.5B in 2022 to $9.22B in 2025, though valuation multiples appear elevated with a P/E of 283.4.
PANW's outlook is supported by AI-driven cybersecurity demand and platformization strategy, but high valuation and competitive pressures present risks. The company's positive cash flow trends and analyst optimism suggest potential upside, though investors should weigh premium pricing against growth sustainability in a dynamic security market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
